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Ten years ago, in 1955 the "Metabolic Establishment" first began to
hear what might be called the
"Great Diabetes Paradox:" impaired glucose tolerance can occur
side by side with normal concentrations of blood insulin or insulinlike activity. This sounded like endocrinologic heresy but it has been
confirmed by almost every worker
in the field, using different assay
methods. Since the paradox is true,
it is provocative, for it suggests
that an important truth may be
hidden beyond it.
One line of approach to this
problem has been to look for insulin antagonists which might prevent normal amounts of insulin
from accomplishing their physiological tasks. Much work has been
done in this area, some of it controversial, all of it exciting. It is not
easy to prepare a critical evaluation
without beginning to seem to be
against progress. But true progress
requires that controversy be resolved.
INSULIN ANTAGONISTS

In 1954, John Vallance-Owen
and Barbara Hurlock described a
method for the assay of insulin-like
activity (ILA) in plasma, using as
an index of response the amount
of glucose disappearing from the
medium in which was incubated a
rat hemi-diaphragm. These workers
found a low level of ILA in fasting
normals, with a brisk rise after glucose ingestion. Crystalline beef insulin added to plasma was recovered
quantitatively.
The next year Vallance-Owen
and co-workers ( 1955) reported
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similar values in obese diabetics requiring no drug treatment. but
found no detectable ILA in the
plasma of uncontrolled, insulinrequiring diabetics; crystalline insulin added in vitro had little or no
effect. Later these authors showed
that if plasma from such patients
were diluted 1 : 4, ILA could be
again demonstrated and added insulin recovered quantitatively. They
concluded that such plasma contained ILA all along, but that some
other plasma component antagonized the action of both the ILA
and added crystalline insulin (Vallance-Owen et al., 1958a). It has
never been clear why the antagonism disappears when both ILA and
the antagonist are diluted to the
same degree.
The next step was to isolate and
identify the antagonist (VallanceOwen et al., 1958b). Fractionation
of serum proteins showed the antagonist to be associated with albumin and because it could be
eluted off the albumin on column
chromatography, it was called "synalbumin antagonist." Serum albumin from both normal and diabetic patients antagonized 1,000
µ.u per ml of beef insulin when
added in a 3.5 to 5.5 % concentration to the medium containing rat
hemi-diaphragm. When the same
albumin fractions were added in
only 1.25 % concentration, there
was no inhibition with normal albumin but persisting, almost complete, inhibition with diabetic albumin. A fair appraisal would be
that everyone has synalbumin antagonist, but that insulin-requiring
diabetics have more of it than
others.
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Other disease entities were soon
admitted to the not-so-exclusive
ranks of synalbumin excess. In
1961, obese maturity-onset diabetics and pre-diabetics with normal
glucose tolerance were shown to
have antagonist at the 1.25 % concentration in blood (Vallance-Owen
and Lilley). In 1963, synalbumin
antagonist was found in 19 of 28
patients with fresh myocardial infarction and n_o family history of
diabetes. This finding persisted after
recovery from infarction, and contrasted with an incidence in only
6 of 28 control patients without
vascular disease or positive family
history (Vallance-Owen and Ashton). Then the antagonist was
found to be present in 6 of 10
grossly obese women without diabetic "chemistries" or family history (Vallance-Owen, 1965) . Further, Alp and Recant (1965) have
demonstrated the presence of synalbumin antagonist (at levels between 1.25 and 3.50%) in ten
pregnant women in the third trimester, again without family history of diabetes.

EFFECT ON METABOLISM IN
ADIPOSE TISSUE
It was soon learned that synalbumin antagonist did not antagonize the effect of insulin on adipose
tissue (Vallance-Owen and Lilley,
1961 ; Lowy, Blanshard, and Phear,
1961). Vallance-Owen has emphasized this (1964a, 1964b), and has
speculated that obesity may be a
manifestation of diabetes rather
than the other way around. Investigation of this phenomenon by
Alp and Recant ( 1964) revealed
that the synalbumin antagonist, like
insulin, actually stimulated the oxidation of glucose by adipose tissue.
The similarity was particularly close
in that anti-insulin antibody could
abolish this effect, a finding considered by many to be proof of
identity with insulin. Furthermore,
the effect of crystalline insulin was
enhanced by the presence of synal-

bumin. Fourteen diabetic albumin
samples in 1.25 % concentration
produce on the average 86% inhibition of the effect of 1000 µ,u per ml
of insulin on rat diaphragm. The
same albumin contributed on the
average 41 % of the stimulation of
glucose uptake by adipose tissue
which was ascribed to insulin-like
activity. It is perfectly clear that
such a metabolic picket line could
divert a great deal of blood glucose
away from muscle and into fat.
These divergent actions have not
been investigated by other workers, who have concentrated their
efforts on the study of the diaphragm effect. Sherman ( 1965) has
recently reported confirmation of
the findings of synalbumin antagonist in normal and diabetic plasma
in the same concentration as originally noted. Using the Stadie technique, Davidson and Goodner
( 1965) found that after diaphragm
was dipped in solution containing
synalbumin antagonist, no amount
of washing would enable it to respond properly to insulin. Conversely, prior dipping in an insulin
solution partially but not completely prevented subsequent action
of the antagonist. They also found
that a huge excess of insulin did not
wholly overcome the effects of a
small amount of synalbumin, and
inferred that the inhibition is not
competitive, contrary to the report
of Alp and Recant (1 965) that it
was partially competitive. Of special interest was the finding that
synalbumin also antagonized the
insulin effect of intracellular accumulation of aminoisobutyric acid,
and to a lesser degree of glycogen
synthesis, which actually tended to
increase proportionally as overall
glucose utilization declined. Both
antagonistic human serum albumin
and non-antagonistic beef serum
albumin depressed the incorporation of glycine-2-C14 into muscle
protein. Davidson and Goodner
concluded that the synalbumin antagonist either binds strongly to the
cell membrane, precluding contact
with insulin, or irreversibly alters

the membrane's biochemical response to insulin.
CHEMICAL IDENTITY OF
ANTAGONIST

During the last three years, Vallance-Owen and his colleagues have
been attempting to identify synalbumin. Preliminary studies suggested that it was probably a polypeptide. In 1963, Ensinck et al.
found that when insulin is cleaved
enzymatically in vitro, the 30-amino
acid B chain appears to associate
with albumin. Ensinck and Vallance-Owen ( 1963) reported at the
same time that purified B chain
readily unites with non-antagonistic
albumin in vitro, and thereby restores the usual antagonism to
1000 µ,u per ml. They have demonstrated 10 biochemical similarities between isolated synalbumin
antagonist and B chain, with no
reported dissimilarities (VallanceOwen, 1964b). In 1964, Ensinck
et al. incubated 113 1-Iabelled insulin
with the hepatic enzyme that cleaves
insulin, glutathione-insulin transhydrogenase. They dialyzed the material and found that most of the
radioactivity remained attached to
the albumin on electrophoresis. In
1965, Ensinck, Mahler, and Vallance-Owen repeated this study
with non-labelled insulin in order
to test the effects of various alkylating agents. Reduced or sulfated
B chain was antagonistic as usual,
but if the molecule were oxidized,
or its thiol groups alkylated with
iodacetamide or N-ethylmaleimide,
the antagonism disappeared. It is
generally accepted that the insulin
molecule attaches to a receptor site
on the cell membrane by forming
disulfide bonds. Reduced B chain,
with its own "dangling" disulfide
bonds, could conceivably attach to
the cell membrane and effectively
compete with insulin for attachment sites by the mechanism of
steric hindrance. Ensinck et al.
(1965) have found that albumin-B
chain complex incubated with diaphragm or cell-free muscle extracts
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become non-antagonistic, so apparently B chain has a greater affinity
for cell membrane than for the
albumin molecule.
Vallance-Owen (1946b) has presented the idea that hepatic
glutathione-insulin transhydrogenase cleaves insulin to a greater or
lesser extent corresponding to the
activity of the pituitary-adrenal axis,
but concedes that there is no direct
support for this theory. As indirect
support he cited earlier work on
cats; ordinarily cats do not have
the synalbumin antagonist (Vallance-Owen and Lukens, 1957),
but, it can be demonstrated after
pancreatectomy, although not after
combined pancreatectomy and hypophysectomy.
ROLE IN PATHOGENESIS OF
DIABETES

The presumed role of synalbumin
antagonist in the pathogenesis of
diabetes mellitus can now be traced
as follows: Due to a genetic predisposition, there is excessive hepatic
glutathione-insulin transhydrogenase activity (perhaps due to decrease in inhibitor), which is exaggerated by pituitary-adrenal hyperactivity. Insulin secreted by the pancreatic B cells reaches the liver via
the portal vein and much of it there
is cleaved to the A and B chains.
The B chain binds to albumin, circulates in the blood, and detaches
from albumin at the cellular level
in order to attach to membrane
binding sites. In adipose tissue the
B chain actively supports the uptake of glucose; in muscle it merely
inhibits the · attachment of the intact insulin molecule. Therefore,
glucose tolerance diminishes, blood
sugar rises, the cells become initially hypersecretory and eventually exhausted, and permanent pancreatic diabetes ensues (VallanceOwen, 1964a and b).
Vallance-Owen has been quite
interested in using the presence of
synalbumin antagonist as a biochemical marker for the genetic
diabetic predisposition ( 1964a) .
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Most recently ( 1965), he studied
94 people in 9 families. Of these
38 had normal amounts of antagonist, and 56 had an increased
amount equivalent to that found in
diabetes ; 18 of these had frank
diabetes, and 3 more had spontaneous hypoglycemia. He feels that
the diabetic predisposition is inherited as a Mendelian dominant,
that perhaps 25% of the world population is constituted as diabetic,
but that probably only 10% of this
segment will develop frank diabetes
during life.
CRITICISMS OF ROLE OF
ANTAGONIST

This review summarized a body
of evidence assembled over a
twelve-year period. On the other
side of the argument, there is the
following evidence:
1) Berson and Yalow (1965)
have challenged the experiment using l 1"1 -labelled insulin and the hepatic enzyme (Ensinck et al., 1964),
on the grounds that the radioactivity bound to albumin can occur
without enzymatic intervention and
probably represents damaged insulin
as a result of irradiation.
2) Some workers have found
that albumin is not antagonistic to
glucose uptake by muscle (Cameron, Keen, and Menzinger, 1964)
or, if it is, only to an extent that
could be explained by the association of free fatty acids (Buse and
Buse, 1964) .
3) A more troublesome question
is to explain the presence of synalbumin antagonist in pancreatectomized animals who do not possess
the antagonist in the intact state?
Vallance-Owen (1964b) has explained this by saying that previously secreted insulin still circulates and contributes B chain to
form the antagonist. He argues that
hypophysectomy prevents this by
suppre8ising the activity of the hepatic erzyme that cleaves insulin,
a.n d th1tt administration of steroids
reverses this suppression. It is difficult to understand how a metabolite

of insulin could appear only after
insulin production has been extinguished.
4) One feels uneasy about the
basic premise of this concept of
diabetes; can we reasonably base
our entire theory on the presence of
a factor which can only be demonstrated as something in human
plasma which antagonizes the effects of beef insulin on rat diaphragm? This is several steps removed from the clinical situati~n,
and is subject to criticism since beef
albumin does not antagonize beef
insulin under these conditions
(Davidson and Goodner, 1965).
5) The same objection might be
made to a specific pathogenetic role
of an antagonist which occurs in
such a large segment of the population. If everyone possesses synalbumin antagonist, as demonstrated
on rat diaphragm, and 25 % possess
an excessive amount, why should
only 2.5% ever develop even chemical diabetes? Explaining this selectivity is really not much easier
then explaining the incidence of
clinical diabetes without ever invoking synalbumin at all. A factor
which is invoked to explain not
only diabetes, but also myocardial
infarction, obesity, and the third
trimester of pregnancy does not
really explain anything.
6) Even if the synalbumin antagonist were of metabolic importance to man, how would its excess
lead to diabetes? According to Alp
and Recant (1964, 1965), the increased glucose uptake by adipose
tissue ought to help counteract the
decreased uptake by muscle, especially as the bulk of adiposity increases. If so, should not progressive
obesity lead to progressive improvement in glucose tolerance? And in
that case, why should cell secretion
become exhau~ted? On this point
the theory does not agree with
clinical facts.
7) Berson (1965) has recently
quoted Mirsky as showing that continuous intravenous infusion of reduced B chain in dogs had no effect
on glucose tolerance.
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CONCLUSION

In conclusion, the synalbumin
antagonist exists, and may be important in the pathogenesis of human diabetes, but its role has not
been proved. The proof will require
elucidation of the problem of species specificity, and ability to measure accurately the levels of synalbumin antagonist.
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